{"id":952908,"date":"2026-04-20T09:18:31","date_gmt":"2026-04-20T13:18:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/"},"modified":"2026-04-20T09:18:31","modified_gmt":"2026-04-20T13:18:31","slug":"anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/","title":{"rendered":"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Focused on protecting and returning value of\u00a0<em>Jemperli<\/em> and imsidolimab royalties to shareholders<\/li>\n<li style=\"margin-bottom:6pt\">Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash<\/li>\n<\/ul>\n<p>SAN DIEGO, April  20, 2026  (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.<\/p>\n<p>Anaptys will now exclusively manage the financial collaborations for <em>Jemperli<\/em> with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders.<\/p>\n<p>\u201cAnaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, <em>Jemperli<\/em> and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and providing a greater than 95% EBIT margin,\u201d said Daniel Faga, president and chief executive officer. \u201cThis structure positions us to operate without complexity and deliver maximum value to shareholders.\u201d<\/p>\n<p>The taxable spin-off was completed today following the distribution to Anaptys shareholders of one share of First Tracks Bio common stock for every one share of Anaptys common stock owned as of the close of business on April 6, 2026, the record date for the distribution.<\/p>\n<p>Anaptys will continue to trade on Nasdaq under the ticker symbol \u201cANAB\u201d. First Tracks Bio common stock will begin regular-way trading today on the Nasdaq Global Select Market under the symbol \u201cTRAX\u201d.<\/p>\n<p>\n        <strong>About AnaptysBio<\/strong>\n      <\/p>\n<p>Anaptys exclusively manages the financial collaborations for <em>Jemperli<\/em> with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=INF2KpJCvmxwLkkAC4TieLsVfNnQDX8wS3FLHHH4RIik5Py5kjxQwLcuF1echHBc37F6ZnlFDM6C6vGpnx0M6tB0_cc8UZk56ykcneVmFyU=\" rel=\"nofollow\" target=\"_blank\">www.AnaptysBio.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SoZF6PXIMsA8PDLySMYwzr_lq51aTyMxu-575HbxZPsQXnWJK0qZiP67uPUEmo5tHe8Z5bEh2YLAB22Co6A2_CA9soHX0yiXf7hhLi47CkM=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to whether Anaptys is able to protect its financial collaborations; and its ability to return value to its shareholders. Statements including words such as \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company\u2019s ability to protect its financial collaborations and return value to its shareholders, the company\u2019s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading \u201cRisk Factors\u201d in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.<\/p>\n<p>This press release also includes a reference to EBIT margin which is a measure not presented in accordance with generally accepted accounting principles in the United States of America (\u201cGAAP\u201d), which Anaptys believes provides important perspective with respect to operational profitability. Non-GAAP financial measures may exclude items that are significant in understanding and assessing Anaptys\u2019 financial results, should not be considered in isolation or as an alternative to GAAP measures, and should be considered only as a supplement to, and not as superior to, GAAP measures. Anaptys cannot predict with certainty the magnitude or scope of certain items that would be included in the most directly comparable GAAP measure to EBIT margin for the relevant future periods, and such items may be significant. Due to these uncertainties, Anaptys cannot provide a quantitative reconciliation of EBIT margin to the most directly comparable GAAP financial measure without unreasonable effort.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Anaptys Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HGOrjVPWMUdGYwhaSEWJadrXpRR7I4Rz9NrjqSWvhu15Uo8XeJf58wfIAc0Af4_I4EG2L09GmMJiNgFoFUU8ciRf9ix-ifR9WpUd2JtWDz7yQEuU3CzkgJi5uuGCKicA\" rel=\"nofollow\" target=\"_blank\">investors@anaptysbio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWZiNTFkZDktMmI3ZC00OWNkLTg1NGEtYzVmMjM4MmFiNmMzLTEwMzE2OTgtMjAyNi0wNC0yMC1lbg==\/tiny\/AnaptysBio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Focused on protecting and returning value of\u00a0Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders. \u201cAnaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, Jemperli and imsidolimab, with streamlined operations requiring &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952908","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Focused on protecting and returning value of\u00a0Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders. \u201cAnaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, Jemperli and imsidolimab, with streamlined operations requiring &hellip; Continue reading &quot;Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T13:18:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations\",\"datePublished\":\"2026-04-20T13:18:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/\"},\"wordCount\":666,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/\",\"name\":\"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=\",\"datePublished\":\"2026-04-20T13:18:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/","og_locale":"en_US","og_type":"article","og_title":"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - Market Newsdesk","og_description":"Focused on protecting and returning value of\u00a0Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) &#8212; AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders. \u201cAnaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, Jemperli and imsidolimab, with streamlined operations requiring &hellip; Continue reading \"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T13:18:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations","datePublished":"2026-04-20T13:18:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/"},"wordCount":666,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/","name":"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=","datePublished":"2026-04-20T13:18:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Mjc3MiM3NTQyNDM2IzIwMjAxMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952908"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952908\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}